66 related articles for article (PubMed ID: 184804)
21. Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium.
Brunkhorst D; von der Leyen H; Meyer W; Schmidt-Schumacher C; Scholz H
Arzneimittelforschung; 1988 Sep; 38(9):1293-8. PubMed ID: 2852013
[TBL] [Abstract][Full Text] [Related]
22. [Phosphodiesterase inhibition as a therapeutic principle].
Scholz H
Z Kardiol; 1994; 83 Suppl 2():1-5. PubMed ID: 8091820
[TBL] [Abstract][Full Text] [Related]
23. Selective phosphodiesterase inhibition and alterations of cardiac function by alkylated xanthines.
Mushlin P; Boerth RC; Wells JN
Mol Pharmacol; 1981 Jul; 20(1):179-89. PubMed ID: 6270531
[No Abstract] [Full Text] [Related]
24. Haemodynamic effects of Ro 13-6438, a new inotropic agent with vasodilating properties.
Braun S; Shargorodsky B; Talit U; Laniado S
Drugs Exp Clin Res; 1986; 12(5):381-4. PubMed ID: 3720522
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular effects of a new inotropic agent, U. K. 14275, in patients with coronary heart disease.
Hutton I; Hillis WS; Langhan CE; Conely JM; Lawrie TD
Br J Clin Pharmacol; 1977 Oct; 4(5):513-7. PubMed ID: 911601
[TBL] [Abstract][Full Text] [Related]
26. Effect of 2-(4-benzyl-piperidino)-1-(4-hydroxyphenyl)-1-propranolol on adenylate cyclase and 3,5'-cyclic AMP phosphodiesterase in vitro.
Yamashita Y; Kawai M; Hotta K
Jpn J Pharmacol; 1976 Jun; 26(3):391-4. PubMed ID: 185445
[No Abstract] [Full Text] [Related]
27. Inotropic therapy of heart failure. Editorial comments on: Vasodilation and mechanoenergetic inefficiency dominates the effect of the "Ca2+ sensitizer" MCI-154 in intact pigs.
Duncker DJ; Verdouw PD
Scand Cardiovasc J; 2002 May; 36(3):131-5. PubMed ID: 12079634
[No Abstract] [Full Text] [Related]
28. Cyclic AMP phosphodiesterase inhibition by coumarins and furanocoumarins.
Sardari S; Nishibe S; Horita K; Nikaido T; Daneshtalab M
Pharmazie; 1999 Jul; 54(7):554-6. PubMed ID: 10445247
[No Abstract] [Full Text] [Related]
29. New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors.
Devillers I; Pevet I; Jacobelli H; Durand C; Fasquelle V; Puaud J; Gaudillière B; Idrissi M; Moreau F; Wrigglesworth R
Bioorg Med Chem Lett; 2004 Jun; 14(12):3303-6. PubMed ID: 15149695
[No Abstract] [Full Text] [Related]
30. 2-(Alkylthio)-1,2,4-triazolo[1,5-a]pyrimidines as adenosine cyclic 3',5'-monophosphate phosphodiesterase inhibitors with potential as new cardiovascular agents.
Novinson T; Springer RH; O'Brien DE; Scholten MB; Miller JP; Robins RK
J Med Chem; 1982 Apr; 25(4):420-6. PubMed ID: 6279846
[TBL] [Abstract][Full Text] [Related]
31. Positive inotropic effect of levosimendan is correlated to its stereoselective Ca2+-sensitizing effect but not to stereoselective phosphodiesterase inhibition.
Kaheinen P; Pollesello P; Hertelendi Z; Borbély A; Szilágyi S; Nissinen E; Haikala H; Papp Z
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):74-8. PubMed ID: 16433895
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and cardiotonic activity of a series of substituted 4-alkyl-2(1H)-quinazolinones.
Bandurco VT; Schwender CF; Bell SC; Combs DW; Kanojia RM; Levine SD; Mulvey DM; Appollina MA; Reed MS; Malloy EA
J Med Chem; 1987 Aug; 30(8):1421-6. PubMed ID: 3039135
[TBL] [Abstract][Full Text] [Related]
33. Effects of DN-9693, a selective inhibitor of cyclic AMP phosphodiesterase, in isolated and perfused canine large coronary arteries.
Nakane T; Chiba S
Jpn J Pharmacol; 1988 Dec; 48(4):507-9. PubMed ID: 2468805
[TBL] [Abstract][Full Text] [Related]
34. Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate.
Movsesian MA
J Am Coll Cardiol; 1999 Aug; 34(2):318-24. PubMed ID: 10440139
[TBL] [Abstract][Full Text] [Related]
35. Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide.
Jones GH; Venuti MC; Alvarez R; Bruno JJ; Berks AH; Prince A
J Med Chem; 1987 Feb; 30(2):295-303. PubMed ID: 3027338
[TBL] [Abstract][Full Text] [Related]
36. DN.9693, a phosphodiesterase inhibitor, compared with prostaglandin E1 and prostacyclin in four platelet "function" tests.
O'Brien JR; Etherington MD; Salmon GP
Thromb Res; 1988 Apr; 50(1):237-41. PubMed ID: 2840751
[No Abstract] [Full Text] [Related]
37. Cardiotonic agents. 2. (Imidazolyl)aroylimidazolones, highly potent and selective positive inotropic agents.
Hagedorn AA; Erhardt PW; Lumma WC; Wohl RA; Cantor E; Chou YL; Ingebretsen WR; Lampe JW; Pang D; Pease CA
J Med Chem; 1987 Aug; 30(8):1342-7. PubMed ID: 3039132
[TBL] [Abstract][Full Text] [Related]
38. The cyclic AMP system and drug development.
Smith CG
Adv Enzyme Regul; 1974; 12():187-203. PubMed ID: 4156822
[No Abstract] [Full Text] [Related]
39. Some aspects of the cardiovascular pharmacology of UK 14,275 in patients with coronary artery disease.
Jennings K; Jackson PG; Monaghan M; Jewitt DE
Br J Clin Pharmacol; 1978 Jan; 5(1):13-8. PubMed ID: 619931
[TBL] [Abstract][Full Text] [Related]
40. Inhibitors of cyclic AMP phosphodiesterase. 4. Synthesis and evaluation of potential prodrugs of lixazinone (N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro-2- oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide, RS-82856).
Venuti MC; Alvarez R; Bruno JJ; Strosberg AM; Gu L; Chiang HS; Massey IJ; Chu N; Fried JH
J Med Chem; 1988 Nov; 31(11):2145-52. PubMed ID: 2846840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
